Open AccessThe Effect of Nintedanib on T-Cell Activation, Subsets and Functions
Author(s) -
Kenia Ubieta,
Matthew Thomas,
Lutz Wollin
Publication year - 2021
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s288369
Subject(s) - nintedanib , cd28 , idiopathic pulmonary fibrosis , t cell , peripheral blood mononuclear cell , cd8 , pulmonary fibrosis , immunology , fibrosis , interferon gamma , cytokine , medicine , chemistry , cancer research , immune system , lung , in vitro , biochemistry
T cells are important regulators of inflammation and, via release of mediators, can contribute to pulmonary fibrosis. Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease (ILD) and chronic fibrosing ILDs with a progressive phenotype. However, how nintedanib targets T cells has not been elucidated.